Loading company…
Rarecells develops liquid biopsy technology to detect circulating tumor cells in blood samples.
Rarecells develops liquid biopsy diagnostics, including ISET® technology, which identifies circulating tumor cells in blood samples to support early cancer detection. The company works with diagnostic and pharmaceutical companies and serves healthcare institutions, research centers and hospitals. Founded in 2010, it is based in Paris, France. In December 2021, it raised USD 13.00 mn in Series A funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in